YuvaBio® Y100™: A Mitochondrial Biogenesis Approach to Cellular Renewal

Cellular energy production depends on mitochondria but the capacity of a cell to produce energy is ultimately determined by the number and quality of the mitochondria it contains. When mitochondrial infrastructure is intact, energy production, stress defense, and repair processes function efficiently. When that infrastructure erodes, no single cofactor or substrate can fully compensate for the loss of these critical organelles [1,2].

This distinction has guided our research at Yuva Biosciences. Our work on Y100™ has focused on mitochondrial biogenesis: the process by which cells build new, functional mitochondria. The biological consequence of biogenesis extends across multiple cellular systems, including energy production, that depend on healthy mitochondrial networks.

Why mitochondrial biogenesis 

Every cell contains hundreds to thousands of mitochondria, and their collective capacity determines how much ATP, the fuel for virtually every critical cellular function, a cell can produce. But healthy mitochondria do more than generate energy. They regulate oxidative stress defenses, modulate inflammatory signaling, and support the maintenance of structural proteins [1]. When damaged mitochondria outnumber healthy ones, all these systems suffer and not because the cell lacks nutrients, but because it lacks functional machinery [2].

Mitochondrial biogenesis is the cell's built-in renewal program. It involves a coordinated cascade of nuclear and mitochondrial gene expression which begin with upstream transcriptional regulators in the nucleus and culminating in the assembly of new electron transport chain complexes and fresh mitochondrial DNA within the organelle itself [3]. This is not a quick fix; it is an investment in the cell's long-term capacity to function as intended.

Y100™: a next-generation mitochondrial active for cellular renewal

Terminalia chebula is a deciduous tree native to South and Southeast Asia with a long history in traditional Ayurvedic practice, where the dried fruit has been used for centuries as a rejuvenative tonic known as Haritaki [4]. Y100™ is derived from Terminalia chebula and developed by Yuva Biosciences through additional purification and enrichment steps designed to concentrate a bioactive constituent with defined physicochemical properties [5]. Notably, when unoptimized Terminalia chebula extract was evaluated under identical experimental conditions, it did not demonstrate comparable biological activity or any efficacy, confirming that the raw material alone is insufficient and that these additional processing steps are integral to Y100's performance [6].

Our research has established that Y100 engages the mitochondrial biogenesis pathway at multiple levels, upregulating both upstream transcriptional regulators that initiate biogenesis and downstream mitochondrial markers that confirm the presence of new organelles and enhanced functional capacity [6]. This reflects coordinated activation of the nucleus-to-mitochondria communication axis described above [3].

That pathway engagement translates into measurable cellular improvements. Across our experimental program, Y100 has demonstrated dose-dependent increases in ATP levels using CellTiter-Glo® luminescent assays [6,7], antioxidant activity exceeding reference compounds [5,8], modulation of inflammatory markers through restored mitochondrial integrity [1,6], and improvements in extracellular matrix-related endpoints relevant to tissue integrity [6]. 

References

[1] Nunnari, J., & Suomalainen, A. (2012). Mitochondria: In sickness and in health. Cell, 148(6), 1145–1159
[2] Picard, M., & McEwen, B. S. (2018). Psychological stress and mitochondria: A systematic review. Psychosomatic Medicine, 80(2), 141–153.  
[3] Campos, J. C., Bozi, L. H. M., & Ferreira, J. C. B. (2022). Mitochondrial Biogenesis and Dynamics in Health and Disease. In: Camara, N.O.S., et al. (eds) Essential Aspects of Immunometabolism in Health and Disease. Springer, Cham. 
[4] Bag, A., Bhattacharyya, S. K., & Chattopadhyay, R. R. (2013). The development of Terminalia chebula Retz. (Combretaceae) in clinical research. Asian Pacific Journal of Tropical Biomedicine, 3(3), 244–252.
[5] Yoshida, T., Amakura, Y., & Yoshimura, M. (2010). Structural features and biological properties of ellagitannins in some plant families of the order Myrtales. International Journal of Molecular Sciences, 11(1), 79–106.
[6] Data on file, Yuva Biosciences, Inc. Mitochondrial biogenesis pathway engagement and cellular improvement evaluation of Y100 in cell-based models.
[7] Crouch, S. P. M., et al. (1993). The use of ATP bioluminescence as a measure of cell proliferation and cytotoxicity. Journal of Immunological Methods, 160(1), 81–88.
[8] Data on file, Yuva Biosciences, Inc. Comparative antioxidant activity assessment of Y100 versus reference compounds.